“Smart investors will look for biotech stocks that have drug pipelines full of good prospects, as well as balance sheets strong enough to withstand any unforeseen problems,” acknowledges the author […]
read more
Having Posted Tremendous Gains In Recent Months, Are Either Of These 2 Small-Cap Biotech Stocks Buys?
“This year didn’t start out with a bang for these two biotechs, but their performances over the past few months have been breathtaking,” observes the author of today’s article in […]
read more
The Next Biotechs To Be Bought Up
When it comes to the question of which biotech companies could be the next M&A targets, one analyst cited in today’s article says the “easy answer” is oncology companies, as […]
read more
Market History Suggests This “Breakthrough” ETF Is A Smart Post-Election Idea
Investors looking for a post-election idea may want to consider the ETF highlighted in today’s article, which tracks an index “comprised of small- and mid-cap stocks of biotechnology companies that […]
read more
New Stocks To Watch In Biotech, Cleantech, Psychedelics & More
Today’s article highlights a plethora of new stocks to watch in the biotech, tech, cleantech, psychedelics and cannabis spaces, among others. In regards to the biotech names, the author notes […]
read more
4 ‘Strong Buy’/‘Buy’ Biotech Stocks
The author of today’s article notes that, while the “upside in biotech sector has been led by positive developments at small companies, primarily the ones developing a vaccine or treatment […]
read more
3 Top Stock Picks From The Outperforming Biotech Sector
“With the number of new drugs and biologics going up day by day, there has never been a better time to invest in biotech stocks,” declares the author of today’s […]
read more
Newer Biotech Issues To Watch
“With companies like Pfizer (NYSE:PFE) giving possible hope for an end of year vaccine and a recent gap up in IBB (Nasdaq Biotechnology ETF), now could be a good time […]
read more
The Investment Thesis For Biotech (And Especially Biopharma)
Despite biotech’s outperformance year-to-date, the authors of today’s article still see the industry as attractive – and they outline three key strategic themes driving their investment thesis for biotech (and […]
read more
This Buy-Rated Biotech With An Effective Alzheimer’s Drug Has Upside Potential Of Over 100%
After an initial analysis of clinical data back in May failed to demonstrate a statistically significant impact on the biomarkers associated with the disease, a re-analysis has found that the […]
read more